Shareholders That Lost Money on Sangamo Therapeutics, Inc. (SGMO) Should Contact Levi & Korsinsky About Securities Fraud Investigation - SGMO
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Sangamo Therapeutics (SGMO) for potential securities fraud. This follows Pfizer's decision to return development rights for a hemophilia A gene therapy, impacting Sangamo's prospects.
January 10, 2025 | 3:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sangamo Therapeutics is under investigation for potential securities fraud after Pfizer returned rights for a key gene therapy, raising concerns about the company's future prospects.
The investigation into potential securities fraud and the return of rights by Pfizer are significant negative developments for Sangamo. These events could lead to a loss of investor confidence and a decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100